2008
DOI: 10.1002/cbic.200800246
|View full text |Cite
|
Sign up to set email alerts
|

Engineering Cytochrome P450 Enzymes for Improved Activity towards Biomimetic 1,4‐NADH Cofactors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
101
0
1

Year Published

2010
2010
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 123 publications
(105 citation statements)
references
References 18 publications
3
101
0
1
Order By: Relevance
“…In addition to recycling costly natural NAD(P) cofactors, another promising direction is replacing NAD(P) with more stable and low-cost artificial biomimetic NAD(P) analogs Lo and Fish, 2002;Ryan et al, 2008). Lowe and his coworkers have developed a range of NAD(P)H analogs based on the structure of a triazine dry template Ansell et al, 1997aAnsell et al, ,b, 1999Burton et al, 1996).…”
Section: Cost Analysis and Perspectivesmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition to recycling costly natural NAD(P) cofactors, another promising direction is replacing NAD(P) with more stable and low-cost artificial biomimetic NAD(P) analogs Lo and Fish, 2002;Ryan et al, 2008). Lowe and his coworkers have developed a range of NAD(P)H analogs based on the structure of a triazine dry template Ansell et al, 1997aAnsell et al, ,b, 1999Burton et al, 1996).…”
Section: Cost Analysis and Perspectivesmentioning
confidence: 99%
“…N-benzyl-1,4-dihydrononicotinamide and its derivatives, which are somewhat structurally similar to natural NAD, represent another type of biomimetic NADH analogs, which have been utilized with wild-type enzymes Lo and Fish, 2002;Lutz et al, 2004). Cytochrome P450, a heme-containing enzyme, has been engineered for improving its performance on these NADH biomimics (Ryan et al, 2008). It is expected that further engineering wild-type oxidoreductases would increase their catalytic efficiencies based on economically advantageous and more stable biomimetic cofactors.…”
Section: Cost Analysis and Perspectivesmentioning
confidence: 99%
“…But this research area is in its infancy [89,90] because there has not been a sufficiently large market/product opportunity to support further R&D before the invention of SyPaB. Several redox enzymes have been engineered for better performance on biomimetic coenzymes [91][92][93]. For similar reasons, there is a lack of thermostable carbohydrate-metabolized enzymes for the SyPaB projects before the invention of SyPaB.…”
Section: Sypab Challenges and Opportunitiesmentioning
confidence: 99%
“…Clearly, it is highly operative to obtain numerous high-TTN non-membrane enzymes suitable for the SyPaB projects. With developments in (i) engineered oxidoreductases that can use biomimetic NAD factors [91][92][93] and (ii) stable enzymes as building blocks of SyPaB [63,65,66,73], we estimate that ultimate hydrogen production costs may decrease to ~$1.30 per kg of hydrogen (Figure 9a), where carbohydrate accounts for ~95% of its production costs, in part because hydrogen has very low product separation and purification costs and the other chemicals in the reaction can be recycled.…”
Section: Sypab Challenges and Opportunitiesmentioning
confidence: 99%
“…The discovery and utilization of more thermostable enzymes suitable for cell-free SyPaB would be a new industrial enzymes gold mine [34]. Costly NAD(P) cofactors are expected to be replaced by low-cost and stable biomimetic analogues [35,36] plus engineered oxidoreductases that can work on the biomimics [37]. Also, several enzymes in the pathways may need further engineering for tolerating toxic metabolites, or increasing enzyme stability, or decreasing product inhibition, or other properties.…”
Section: Closing Remarksmentioning
confidence: 99%